Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
- Associated Conditions
- -
- Associated Therapies
- -
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 141
- Registration Number
- NCT05266001
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Benioff Children's Hospital - Oakland, Oakland, California, United States
A Study of a Vaccine in Combination with Β-glucan and GM-CSF in People with Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 264
- Registration Number
- NCT04936529
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04909515
- Locations
- 🇷🇺
National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev, Moscow, Russian Federation
🇸🇬ICON Cancer Centre Novena, Singapore, Singapore
🇷🇺Research Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 66
- Registration Number
- NCT04892498
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳The Sixth Affiliated Hospital ，Sun Yat-seen University, Guangzhou, China
IBI188 Combination Therapy in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04861948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Metastatic Solid Cancer Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- ImmunSYS, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04739618
- Locations
- 🇺🇸
Vincere Cancer Center, Scottsdale, Arizona, United States
🇺🇸Florida Endovascular and Interventional, Miami Lakes, Florida, United States
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 117
- Registration Number
- NCT04238819
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Western Australia, Australia
🇯🇵National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇧🇪UZ Gent, Gent, Oost-Vlaanderen, Belgium
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 63
- Registration Number
- NCT04106180
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
The Effect of the GM-CSF Gel on the Endometrial Thickness in Infertile Women With Thin Endometrium
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT04100655
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03769844
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.